The news hasn’t been downright soul-crushing lately, and those looking for light may only have last week’s June labor report to feel remotely cheerful.
Startup entrepreneurs woke up Friday to learn that venture capital overall and in biotech and medical devices sectors were all lower in the second quarter than the same period in 2015.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Venture capitalists pumped in $15.3 billion in 961 deals in the second quarter, down 12 and 22 percent, respectively in dollars and number of deals from the second quarter of 2015, according to the MoneyTree Report from PricewaterhouseCoopers and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters. In the first quarter, venture capitalists spent $12.7 billion in 1,011 deals – in other words, they invested more in Q2 but through a smaller number of deals.
In biotech, investors poured in $1.69 billion through 100 deals in the second quarter, down from $2.12 billion invested through 124 deals in Q2, 2015. Medical device startups didn’t fare much differently – they raked in $538.8 million through 61 deals, compared with $841.7 million through 83 deals in Q2, 2015.
Here is an infographic based on the data from the MoneyTree Report.
BioLabs Pegasus Park Cultivates Life Science Ecosystem
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Photo: Free Digital Photos user digitalart
